Share this article
Share this article
INDIANAPOLIS, April 23, 2021 /PRNewswire/ Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company s (NYSE: LLY) Taltz
® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PASI) 100. In three real-world analyses of U.S. claims data ranging from one to three years, patients treated with Taltz stayed on treatment longer, were more adherent to the prescription and had more days on monotherapy compared to the other biologics studied. These results are being presented virtually at the American Academy of Dermatology s Virtual Meeting Experience (AAD VMX), April 23-25, 20
IM Cannabis Corp.: IM Cannabis Reports Fiscal 2020 Results; Provides Preliminary Q1 Results and Q2 Outlook
1; FY 2020: revenues of $15.9 million and gross margin of 55%
1
.
Preliminary unaudited Q1 2021 revenues expected to be in the range of $8.5 - $9.0 million; gross margin expected to be in the range of 50% to 55%.
Q2 2021 revenues expected to be in the range of $17 million - $19 million from continued growth in Israel, resumption of product shipments and growth of revenue in Germany, and inclusion of Trichome operations in the Company s financial results
TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / April 23, 2021 /
IM Cannabis Corp. (
Company ) (CSE:IMCC)(NASDAQ:IMCC), a multi-country operator (
Incyte logo. (PRNewsfoto/Eli Lilly and Company)
INDIANAPOLIS, April 23, 2021 /PRNewswire/ Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incyte s (NASDAQ:INCY) OLUMIANT
® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, OLUMIANT provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by percent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with OLUMIANT showed significant improvements in the severity and extent of disease compared to placebo. In the integrated safety analysis o
IM Cannabis Reports Fiscal 2020 Results; Provides Preliminary Q1 Results and Q2 Outlook phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment
Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity through the 48 weeks of treatment
Data presented today in a late-breaking oral presentation at AAD VMX 2021
Management to host an investor call today at 12:00 p.m. EDT
BOULDER, Colo., April 23, 2021 (GLOBE NEWSWIRE) Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced results from its Phase 3 open-label, long-term safety study (“ARGYLE” or “LTSS”), which were also presented today in a late-breaking oral presentation at the American Academy of Dermatology’s (“AAD”) 2021 Virtual Meeting Experience (“VMX”). The ARGYLE study assessed the long-term safety and efficacy